Literature DB >> 24285828

Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Craig P Chappell1, Natalia V Giltiay, Christiane Dresch, Edward A Clark.   

Abstract

Delivering antigens in vivo by coupling them to mAbs specific for unique receptors on antigen-presenting cells (APCs) is a promising approach for modulating immune responses. Antigen delivery to receptors found on myeloid dendritic cell (DC) subsets, plasmacytoid DCs and B cells has shown them all to be viable targets to stimulate either the cellular or humoral arms of the immune system. It is now evident that antigen-targeting approaches can also be used to invoke antigen-specific inhibition of immune responses. The outcome of activation versus inhibition is determined by a combination of factors that include the choice of APC, the receptor that is targeted, whether to include an adjuvant and, if so, which adjuvant to employ. In addition to their use as a means to modulate immune responses, antigen-targeting systems are also a useful method to investigate the function of DC subsets and the early mechanistic events that underlie the initiation of both cellular and humoral immune responses. In this review, we focus on the literature surrounding the control of B-cell responses when antigen is delivered to various APC subsets.

Entities:  

Keywords:  B cell; antibody; antigen targeting; dendritic cell

Mesh:

Substances:

Year:  2013        PMID: 24285828      PMCID: PMC3904668          DOI: 10.1093/intimm/dxt059

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  76 in total

1.  Differential antigen processing by dendritic cell subsets in vivo.

Authors:  Diana Dudziak; Alice O Kamphorst; Gordon F Heidkamp; Veit R Buchholz; Christine Trumpfheller; Sayuri Yamazaki; Cheolho Cheong; Kang Liu; Han-Woong Lee; Chae Gyu Park; Ralph M Steinman; Michel C Nussenzweig
Journal:  Science       Date:  2007-01-05       Impact factor: 47.728

Review 2.  Targeting antigens to dendritic cells in vivo.

Authors:  Paul J Tacken; Ruurd Torensma; Carl G Figdor
Journal:  Immunobiology       Date:  2006-07-07       Impact factor: 3.144

3.  Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation.

Authors:  Sven Burgdorf; Andreas Kautz; Volker Böhnert; Percy A Knolle; Christian Kurts
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

4.  CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses.

Authors:  Fernanda V V Castro; Alison L Tutt; Ann L White; Jessica L Teeling; Sonya James; Ruth R French; Martin J Glennie
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

5.  Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon.

Authors:  Peter S Jaehn; Kurt S Zaenker; Juergen Schmitz; Andrzej Dzionek
Journal:  Eur J Immunol       Date:  2008-07       Impact factor: 5.532

6.  Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1.

Authors:  Robert W Carter; Clare Thompson; Delyth M Reid; Simon Y C Wong; David F Tough
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

Review 7.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases.

Authors:  Michel Gilliet; Wei Cao; Yong-Jun Liu
Journal:  Nat Rev Immunol       Date:  2008-08       Impact factor: 53.106

8.  Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production.

Authors:  Friederike Meyer-Wentrup; Daniel Benitez-Ribas; Paul J Tacken; Cornelis J A Punt; Carl G Figdor; I Jolanda M de Vries; Gosse J Adema
Journal:  Blood       Date:  2008-02-07       Impact factor: 22.113

9.  BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells.

Authors:  Wei Cao; Li Zhang; David B Rosen; Laura Bover; Gokuran Watanabe; Musheng Bao; Lewis L Lanier; Yong-Jun Liu
Journal:  PLoS Biol       Date:  2007-09-11       Impact factor: 8.029

10.  Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake.

Authors:  Daniel Benitez-Ribas; Gosse J Adema; Gregor Winkels; Ina S Klasen; Cornelis J A Punt; Carl G Figdor; I Jolanda M de Vries
Journal:  J Exp Med       Date:  2006-06-19       Impact factor: 14.307

View more
  17 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  Targeting Antigens to CD180 but Not CD40 Programs Immature and Mature B Cell Subsets to Become Efficient APCs.

Authors:  Kelsey Roe; Geraldine L Shu; Kevin E Draves; Daniela Giordano; Marion Pepper; Edward A Clark
Journal:  J Immunol       Date:  2019-09-04       Impact factor: 5.422

3.  Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.

Authors:  Raquel S Laureano; Jenny Sprooten; Isaure Vanmeerbeerk; Daniel M Borras; Jannes Govaerts; Stefan Naulaerts; Zwi N Berneman; Benoit Beuselinck; Kalijn F Bol; Jannie Borst; An Coosemans; Angeliki Datsi; Jitka Fučíková; Lisa Kinget; Bart Neyns; Gerty Schreibelt; Evelien Smits; Rüdiger V Sorg; Radek Spisek; Kris Thielemans; Sandra Tuyaerts; Steven De Vleeschouwer; I Jolanda M de Vries; Yanling Xiao; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2022-07-04       Impact factor: 7.723

4.  Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.

Authors:  L Xue; T Hickling; R Song; J Nowak; B Rup
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

5.  Targeting antigens through blood dendritic cell antigen 2 on plasmacytoid dendritic cells promotes immunologic tolerance.

Authors:  Craig P Chappell; Natalia V Giltiay; Kevin E Draves; ChangHung Chen; Martha S Hayden-Ledbetter; Mark J Shlomchik; Daniel H Kaplan; Edward A Clark
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

6.  Optimization of multi-epitopic HIV-1 recombinant protein expression in prokaryote system and conjugation to mouse DEC-205 monoclonal antibody: implication for in-vivo targeted delivery of dendritic cells.

Authors:  Roghayeh Rahimi; Massoumeh Ebtekar; Seyed Mohammad Moazzeni; Ali Mostafaie; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2015-02       Impact factor: 2.699

7.  Contributions of direct versus indirect mechanisms for regulatory dendritic cell suppression of asthmatic allergen-specific IgG1 antibody responses.

Authors:  Yanna Ma; Wojciech Dawicki; Xiaobei Zhang; John R Gordon
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

Review 8.  Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.

Authors:  Cleo Goyvaerts; Karine Breckpot
Journal:  J Immunol Res       Date:  2015-10-25       Impact factor: 4.818

9.  Antigen targeting reveals splenic CD169+ macrophages as promoters of germinal center B-cell responses.

Authors:  Henrike Veninga; Ellen G F Borg; Kyle Vreeman; Philip R Taylor; Hakan Kalay; Yvette van Kooyk; Georg Kraal; Luisa Martinez-Pomares; Joke M M den Haan
Journal:  Eur J Immunol       Date:  2015-01-14       Impact factor: 5.532

10.  CD301b+ dendritic cells suppress T follicular helper cells and antibody responses to protein antigens.

Authors:  Yosuke Kumamoto; Toshiro Hirai; Patrick W Wong; Daniel H Kaplan; Akiko Iwasaki
Journal:  Elife       Date:  2016-09-22       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.